Korea's Celltrion Posts Record-High Q1 Sales And Net Profit, Riding On Biosimilar Prospects
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's biosimilar front-runner Celltrion Inc. continued its upward swing in the first quarter of 2011with first quarter sales and net profit reaching record highs
You may also be interested in...
Korea’s Celltrion Initiates Clinical Trials Of Roche’s Rituxan Biosimilar
Celltrion takes a step forward in its biosimilar ambitions by commencing clinical trials of a key pipeline product.
Korea’s Celltrion Initiates Clinical Trials Of Roche’s Rituxan Biosimilar
Celltrion takes a step forward in its biosimilar ambitions by commencing clinical trials of a key pipeline product.
Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News
Up until a few years ago, South Korea's biosimilar front-runner Celltrion Inc.'s main business was manufacturing products for others. But the company inked a deal with U.S.-based Hospira in 2009 to collaborate on manufacturing and marketing eight biosimilars. Celltrion has hinted that a bigger deal with Hospira could be in the works, which would provide the Korean company with a global sales network.